Maria Gabriella Camboni is co-founder and CEO of BiovelocITA, Italy's first accelerator dedicated to biotech.
With the backing of Sofinnova Partners, BiovelocITA's mission is to foster cooperation between entrepreneurs, scientists and investors to accelerate world-class biotech projects to reach preclinical proof of concept.
Until 2013, Gabriella was chief operations officer of EOS, a start-up devoted to translational research in oncology, which she co-founded with Silvano Spinelli in 2006. EOS was sold to Clovis in 2013.
Prior to this, Gabriella held various positions in the pharmaceutical industry, including head of clinical oncology at Boehringer Mannheim Italy, head of development at Novuspharma (a spin-off of Boehringer Mannheim that she co-founded, which is now Cell Therapeutics), and head of medical affairs Europe at Novartis Oncology.
Gabriella obtained her M.D. from the University of Milan; she is a board-certified gastroenterologist and clinical pharmacologist. Gabriella is also a member of the Board of Directors of Mission Therapeutics.